vs
Side-by-side financial comparison of HEALTHY CHOICE WELLNESS CORP. (HCWC) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
HEALTHY CHOICE WELLNESS CORP. is the larger business by last-quarter revenue ($18.7M vs $18.6M, roughly 1.0× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -8.9%, a 74.6% gap on every dollar of revenue.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
HCWC vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $18.6M |
| Net Profit | $-1.7M | $12.3M |
| Gross Margin | 39.1% | — |
| Operating Margin | -7.6% | 56.3% |
| Net Margin | -8.9% | 65.7% |
| Revenue YoY | — | 1808.5% |
| Net Profit YoY | — | 376.5% |
| EPS (diluted) | $-0.05 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.7M | $18.6M | ||
| Q3 25 | $19.0M | $334.0K | ||
| Q2 25 | $20.2M | $1.4M | ||
| Q1 25 | $20.3M | $257.0K | ||
| Q4 24 | — | $977.0K | ||
| Q3 24 | $18.2M | $660.0K | ||
| Q2 24 | — | $736.0K | ||
| Q1 24 | — | $1.4M |
| Q4 25 | $-1.7M | $12.3M | ||
| Q3 25 | $-1.2M | $-8.6M | ||
| Q2 25 | $-339.4K | $-6.9M | ||
| Q1 25 | $-712.4K | $-5.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.7M | $-2.8M | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $411.0K |
| Q4 25 | 39.1% | — | ||
| Q3 25 | 38.8% | — | ||
| Q2 25 | 40.1% | — | ||
| Q1 25 | 38.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -7.6% | 56.3% | ||
| Q3 25 | -3.2% | -2516.5% | ||
| Q2 25 | -0.2% | -701.0% | ||
| Q1 25 | -2.0% | -3350.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -2.0% | -1563.6% | ||
| Q2 24 | — | -1255.0% | ||
| Q1 24 | — | -692.5% |
| Q4 25 | -8.9% | 65.7% | ||
| Q3 25 | -6.4% | -2572.2% | ||
| Q2 25 | -1.7% | -504.8% | ||
| Q1 25 | -3.5% | -2097.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -14.6% | -425.5% | ||
| Q2 24 | — | -1964.4% | ||
| Q1 24 | — | 29.9% |
| Q4 25 | $-0.05 | $0.25 | ||
| Q3 25 | $-0.09 | $-0.17 | ||
| Q2 25 | $-0.03 | $-0.14 | ||
| Q1 25 | $-0.07 | $-0.11 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.29 | $-0.06 | ||
| Q2 24 | — | $-0.30 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $40.0M |
| Total DebtLower is stronger | $7.3M | — |
| Stockholders' EquityBook value | $7.3M | $49.4M |
| Total Assets | $33.5M | $59.0M |
| Debt / EquityLower = less leverage | 1.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $40.0M | ||
| Q3 25 | $3.0M | $37.9M | ||
| Q2 25 | $4.7M | $44.8M | ||
| Q1 25 | $1.8M | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | $1.8M | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | — | $80.2M |
| Q4 25 | $7.3M | — | ||
| Q3 25 | $8.5M | — | ||
| Q2 25 | $9.7M | — | ||
| Q1 25 | $10.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $11.6M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $7.3M | $49.4M | ||
| Q3 25 | $5.9M | $36.4M | ||
| Q2 25 | $5.8M | $44.5M | ||
| Q1 25 | $2.1M | $50.5M | ||
| Q4 24 | — | $55.1M | ||
| Q3 24 | $2.9M | $58.5M | ||
| Q2 24 | — | $60.4M | ||
| Q1 24 | — | $74.1M |
| Q4 25 | $33.5M | $59.0M | ||
| Q3 25 | $33.7M | $51.1M | ||
| Q2 25 | $36.4M | $60.7M | ||
| Q1 25 | $34.1M | $67.9M | ||
| Q4 24 | — | $90.6M | ||
| Q3 24 | $33.2M | $99.0M | ||
| Q2 24 | — | $107.8M | ||
| Q1 24 | — | $118.3M |
| Q4 25 | 1.00× | — | ||
| Q3 25 | 1.43× | — | ||
| Q2 25 | 1.69× | — | ||
| Q1 25 | 5.01× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.95× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-855.1K | $18.4M |
| Free Cash FlowOCF − Capex | $-927.1K | — |
| FCF MarginFCF / Revenue | -5.0% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $675.4K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-855.1K | $18.4M | ||
| Q3 25 | $-308.7K | $-8.7M | ||
| Q2 25 | $1.1M | $-7.5M | ||
| Q1 25 | $1.1M | $-7.5M | ||
| Q4 24 | — | $-24.0M | ||
| Q3 24 | — | $765.0K | ||
| Q2 24 | — | $-10.9M | ||
| Q1 24 | — | $-4.0M |
| Q4 25 | $-927.1K | — | ||
| Q3 25 | $-351.3K | — | ||
| Q2 25 | $988.6K | — | ||
| Q1 25 | $965.3K | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -5.0% | — | ||
| Q3 25 | -1.8% | — | ||
| Q2 25 | 4.9% | — | ||
| Q1 25 | 4.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HCWC
| Retail Grocery | $17.1M | 91% |
| Food Service Restaurant | $1.7M | 9% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
